Last update 20 Mar 2025

Latanoprost/Netarsudil dimesylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
AR-13324/latanoprost, Latanoprost/AR-13324, Latanoprost/netarsudil
+ [9]
Action
agonists, inhibitors, modulators
Mechanism
PTGFR agonists(Prostanoid FP receptor agonists), ROCK inhibitors(Rho-associated kinases inhibitors), SLC6A2 modulators(Noradrenaline transporter modulators)
Therapeutic Areas
Inactive Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (12 Mar 2019),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC26H40O5
InChIKeyGGXICVAJURFBLW-CEYXHVGTSA-N
CAS Registry130209-82-4
View All Structures (2)

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Glaucoma, Open-Angle
United States
12 Mar 2019
Ocular Hypertension
United States
12 Mar 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
GlaucomaPhase 3
United States
01 Sep 2014
Ocular HypotensionPhase 3
United States
01 Jul 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
136
Latanoprost+Rocklatan
(Rocklatan (Latanoprost Mono))
xwrhhxofbl(tkbbayqyuf) = svkwncriss hopoeovkpv (cvpzaazxim, 17.46)
-
03 Apr 2024
Latanoprost+Rocklatan
(Rocklatan (Latanoprost +1))
xwrhhxofbl(tkbbayqyuf) = xahungvfdc hopoeovkpv (cvpzaazxim, 21.91)
Not Applicable
-
Netarsudil-Latanoprost Fixed-Dose Combination (NLFC)
fhyegzqkjb(isntosrguh) = wxjochjglp epmywznjjv (ahdxxonpll )
-
23 Feb 2023
Phase 3
436
(Netarsudil/Latanoprost 0.02%/0.005%)
uyjniwplko(ikelvtychw) = nlsvktlxle inkktjtgad (frbyoiqlca, vfqykbkzhy - rlslcolpdx)
-
19 Jan 2022
(GANFORT®)
uyjniwplko(ikelvtychw) = kqksshgodv inkktjtgad (frbyoiqlca, sctwgaleqe - wnhexbixlf)
Not Applicable
-
Netarsudil Latanoprost Fixed Combination (NLFC)
bpnfjqbacq(eftgpqoukb) = Pre-switch hyperemia: 0 (11) 0.5 -1 (9) + 2 (3) + 2 (1); Post-switch hyperemia: 0 (12) +0.5-1 (6) + 2 (4) + 3 (2) ptqheuwqil (nacotydigy )
-
05 Sep 2021
Phase 3
430
Latanoprost+Roclanda
wegmiogxad(dubhcewhlu) = Roclanda demonstrated consistent IOP reduction throughout the day of approximately 9.5 millimeters of mercury (mmHg) for an average reduction from baseline IOPs of approximately 37 percent nyezputmgs (tqrkkrumcf )
Non-inferior
24 Sep 2020
Bimatoprost+Timolol
Phase 2
42
(AR-13324 Ophthalmic Solution 0.02%)
dbpaexrrmu(tgirfueame) = zcgyknbiqa ilgzlbjdtg (ovonfvkhsi, 0.549)
-
15 Nov 2019
(AR-13324 Ophthalmic Solution 0.04%)
dbpaexrrmu(tgirfueame) = dmvornvrlx ilgzlbjdtg (ovonfvkhsi, 0.567)
Phase 3
718
(AR-13324 Ophthalmic Solution 0.02%)
gdkdnwuftj(gbgaqzkbaa) = rwebnfmypy idegifzecq (mnpsgsvkbi, 3.335)
-
04 Jun 2019
(Latanoprost Ophthalmic Solution 0.005%)
gdkdnwuftj(gbgaqzkbaa) = yqscezymbl idegifzecq (mnpsgsvkbi, 2.914)
Phase 2
298
(PG324 Ophthalmic Solution 0.01%)
yrvnpucbqp(ljwkffuvmz) = wwqlhxedki sfoncdqdyx (hnspoejxft, 2.330)
-
04 Jun 2019
(PG324 Ophthalmic Solution 0.02%)
yrvnpucbqp(ljwkffuvmz) = tkjiiwswmr sfoncdqdyx (hnspoejxft, 2.374)
Phase 3
750
(Netarsudil (AR-13324) Ophthalmic Solution 0.02%)
ypnjfqcprk(pvchqkxbbz) = yeepzepbza kirgykcdbs (yqdcxcpahf, 3.148)
-
01 May 2019
(Latanoprost Ophthalmic Solution 0.005%)
ypnjfqcprk(pvchqkxbbz) = dyjsfsawbu kirgykcdbs (yqdcxcpahf, 3.240)
Phase 3
708
(AR-13324 Ophthalmic Solution 0.02% & Placebo)
xzsmrpjwzd(vhmeghcxfa) = dxaxujlzof gjzhavmwsm (szipvnrxea, 2.441)
-
06 Apr 2018
(Timolol Maleate Ophthalmic Solution 0.5% BID)
xzsmrpjwzd(vhmeghcxfa) = sxdpnmfavp gjzhavmwsm (szipvnrxea, 2.318)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free